Nathan Fox

I currently work in Strategic Market Access and Policy, advising a range of clients across pharmaceuticals, devices, industry groups (e.g., Medicines Australia), universities, governments, and other stakeholders, domestic and international on strategic, commercial and analysis matters.

A key objective of this role is to advise clients on the funding and economic evaluation mechanisms and pathways in the Australian and international markets they must successfully navigate in order for their healthcare intervention to achieve market entry. I am the health economics lead for funding submissions, currently advising multiple international clients and developing submissions to Australian and New Zealand HTA agencies including the PBAC and PHARMAC.

I also use financial and economic modelling skills to provide client solutions in a more general sense (economic impact assessments, product value proposition, market feasibility and landscape assessments, etc.).

I am currently responsible for one direct report and am largely responsible for the delivery of all project aspects from project scoping, management, execution and budgeting. I am a published academic author and regular industry event speaker. My work has shaped contemporary policy debate, including Australia's HTA Review.

Notable policy and advocacy work has included:

• Preparing the Medicines Australia position paper on changes to the PBAC discount rate
• Journal article outlining the economic impact of the availability of COVID vaccines on Australian society (on behalf of global pharma client)
• White Paper outlining the case for a health technology horizon scanning function in New Zealand
• Submission to the NSW Government including a CBA of the development of an MRNA industry in NSW
• Submission to the NSW Government outlining the economic impact of the Macquarie Park Innovation District (MPID) to the NSW and Australian economy.

I worked as part of a team of assessors contracted by the Australian Department of Health to assist the technology evaluation function of the Medical Services Advisory Committee (MSAC; www.msac.gov.au). Key tasks included:

• Developing and evaluating medical services assessments and proposals for listing on the Medical Benefits Schedule (MBS);
• Project management, including project proposals, budgeting, and liaising and meeting with Department of Health;
• Developing de novo and critiquing economic and financial evaluations;
• Assisting with systematic literature review.

I was a Senior Health Economist within the Health Economics team. I developed and delivered value propositions to secure funding decisions across numerous therapeutic areas including dermatology, rheumatology, gastrointestinal, oncology, rare disorders and infectious diseases. Key tasks included:

• Appraising clinical, epidemiological, economic, and commercial aspects of external submissions as required
• Articulating place in New Zealand therapy, including by KOL engagement
• Developing de novo economic and budget impact models and subsequently writing Technology Appraisal Reports (TAR)
• Defining proposal financial risk drivers
• Articulating proposal value propositions
• Participating in PHARMACs funding prioritisation process